C-reactive protein (CRP)

Where the papers sit

19 papers from the last 6 months study C-reactive protein (CRP) directly · updated from PubMed 3 Oct 2026

• Inflammatory Biomarkers in Acute Care

  Inflammatory biomarkers are being tested as severity, prognosis and treatment-response indicators across acute and chronic disease. IL-6, procalcitonin, CRP and LDH-based ratios recur in appendicitis, COVID-19, vasculitis and pyelonephritis, with mortality and hospital stay as common endpoints. In axial spondyloarthritis, baseline CRP is examined as a modifier of biologic effectiveness rather than only a diagnostic signal. Genetic analyses of CRP and gestational diabetes add uncertainty about causation, so clinical utility remains context-dependent.

  7 papers · 36.8%

• Portable Biomarker Detection

  Multiplex, portable assays are moving inflammatory biomarker testing beyond centralized laboratories. Lateral-flow strips, AIE nanoparticle immunoassays, smartphone readouts and integrated flow formats target rapid quantitative measurement. Serum amyloid A, CRP and progranulin recur in infection and inflammation applications, while plasma signatures extend testing to cerebral amyloid angiopathy. Clinical validation across diseases and analyte panels remains open.

  5 papers · 26.3%

• Host Biomarkers for Infection

  Host-response scores are moving infection assessment toward rapid rule-in and rule-out decisions rather than pathogen testing alone. MeMed BV, procalcitonin, CRP and interferon gamma-induced protein 10 are compared for bacterial infection, TB triage and pediatric acute care. Prospective stewardship work asks whether biomarker algorithms can safely reduce antibiotics, while diagnostic studies emphasize sensitivity and specificity. The need for repeat blood tests and performance across ages and settings remain practical gaps.

  4 papers · 21.1%

• Others — Inflammation and Clinical Risk

  Inflammatory signals are being used in three separate clinical questions: drug-related neuropsychiatric toxicity, infection prediction in lupus, and mood symptoms with neuropathic pain. Abemaciclib and palbociclib are compared through pharmacovigilance, whereas explainable machine learning uses systemic features to estimate infection risk. IL-1α and CRP are linked to anxiety and depression, but this does not establish a shared mechanism across the applications. The cluster therefore has no single disease or clinical trajectory.

  3 papers · 15.8%